325 results match your criteria Pneumocystis carinii jiroveci Pneumonia


Immunosuppressive Treatment and Its Effect on the Occurrence of Pneumocystis jiroveci, Mycoplasma pneumoniae, Chlamydophila pnemoniae, and Legionella pneumophila Infections/Colonizations Among Lung Transplant Recipients.

Transplant Proc 2018 Sep 13;50(7):2053-2058. Epub 2018 Mar 13.

Department of Cardiac, Vascular and Endovascular Surgery and Transplantology, Medical University of Silesia in Katowice, Silesian Center for Heart Diseases, Zabrze, Poland. Electronic address:

Background: The aim of the study was to assess the frequency of infections caused by Pneumocystis jiroveci, Chlamydophila pneumoniae, Legionella pneumophila, and Mycoplasma pneumoniae among lung transplant recipients in the context of immunosuppression.

Methods: The study group consisted of 94 patients (37 women and 57 men; mean age 42.03 years) transplanted between 2009 and 2016 at the Silesia Center for Heart Diseases (SCCS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.transproceed.2017.12.059DOI Listing
September 2018
19 Reads

[Epidemiological characteristics of infection and colonization in non-AIDS patients].

Zhonghua Yi Xue Za Zhi 2018 Aug;98(30):2414-2417

Department of Respiratory and Critical Care Medicine, Peking University First Hospital, Beijing 100034, China.

To analyze the epidemiological characteristics of infection and colonization in non-AIDS patients. From January 2010 to December 2017, bronchoalveolar lavage fluid (BALF) was detected by Grocott's methenamine silver (GMS) staining and real-time fluorescence quantitative PCR (qPCR) in non-AIDS patients with bronchoscopic alveolar lavage at Peking University First Hospital. At the same time, was detected in the environment of the hospital. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.0376-2491.2018.30.009DOI Listing
August 2018
15 Reads

Pneumocystis Jiroveci Pneumonia and Newly Diagnosed Human Immunodeficiency Virus (AIDS) in a 63-Year-Old Woman.

Am J Case Rep 2018 Aug 8;19:927-931. Epub 2018 Aug 8.

Faculty of Medicine, University of Jordan, Amman, Jordan.

BACKGROUND Pneumocystis jiroveci pneumonia (PCP) - formerly known as Pneumocyctis carinii pneumonia - with newly diagnosed AIDS is an uncommon presentation in people over 50 years of age. A high level of suspicion is required for this diagnosis when an elderly patient with pneumonia is not responding to broad-spectrum antibiotic treatment. CASE REPORT We describe the case of a 63-year-old woman who presented with dyspnea, cough, and significant hypoxemia requiring high-flow oxygen supplement with bilateral lung infiltrates, treated with broad-spectrum antibiotics for a presumed diagnosis of pneumonia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12659/AJCR.909612DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6095065PMC
August 2018
1 Read

pneumonia in a patient taking Benepali for rheumatoid arthritis.

BMJ Case Rep 2018 Apr 21;2018. Epub 2018 Apr 21.

Rheumatology, Glasgow Royal Infirmary, Glasgow, UK.

We present a case of a 57-year-old woman who contracted pneumonia while on Benepali, the biosimilar version of etanercept for rheumatoid arthritis. She had seropositive erosive disease. She was admitted to clinic with a 2-week history of dyspnoea, dry cough and fever. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2018-224764DOI Listing
April 2018
4 Reads

Nonopportunistic infection leading to rapidly progressive dementia in a patient with HIV/AIDS: A case report.

Medicine (Baltimore) 2018 Mar;97(12):e0162

Karolinska University Hospital Huddinge, Department of Infectious Diseases.

Rationale: Cognitive dysfunction is a common presenting symptom in patients with HIV/AIDS. It is usually directly associated with HIV infection or due to opportunistic infection. Rapidly progressive dementia, however, is rarely observed in acute HIV infection or during immune reconstitution. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00005792-201803230-0001
Publisher Site
http://dx.doi.org/10.1097/MD.0000000000010162DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5895346PMC
March 2018
19 Reads
5.720 Impact Factor

Pneumocystis jirovecii pneumonia in patients with acute myeloid leukaemia.

Intern Med J 2018 Jan;48(1):81-83

Division of Hematology-Oncology, Chang Gung Memorial Hospital, Taoyuan, Taiwan.

The association of Pneumocystis jirovecii pneumonia (PJP) and acute myeloid leukaemia (AML) is not clearly defined. In our experience of 291 patients with AML, 20 (14 males and 6 females, median age 56) developed PJP (incidence 6.8%). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/imj.13668DOI Listing
January 2018
1 Read

Combination of Echinocandins and Trimethoprim/Sulfamethoxazole for the Treatment of Pneumocystis jiroveci Pneumonia After Heart Transplantation.

Transplant Proc 2017 Oct;49(8):1893-1898

Heart Center, Cheng Hsin General Hospital, Taipei, Taiwan. Electronic address:

Background: The echinocandins have shown anti-Pneumocystis jiroveci activity in nonhuman animal models; however, the corresponding human clinical experience has been rarely reported. We report a clinical picture of P jiroveci pneumonia (PJP) and determine the effects of concomitant therapy with echinocandins and trimethoprim (TMP)-sulfamethoxazole (SMZ).

Methods: We investigated a retrospective case series of heart transplantation (HT) recipients with PJP from July 1988 to December 2015. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.transproceed.2017.04.020DOI Listing
October 2017
9 Reads

Determining the Incidence of Pneumocystis Pneumonia in Patients With Autoimmune Blistering Diseases Not Receiving Routine Prophylaxis.

JAMA Dermatol 2017 11;153(11):1137-1141

Center for Blistering Diseases, Department of Dermatology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.

Importance: Pneumocystis pneumonia (PCP) is a potentially lethal opportunistic infection that primary prophylaxis can help prevent. The risk of prophylactic therapy must be weighed against the incidence of PCP in the patient population. Prophylaxis most frequently involves trimethoprim-sulfamethoxazole, with second-line therapies, including atovaquone, dapsone, and pentamide. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamadermatol.2017.2808DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5710438PMC
November 2017
24 Reads

Infectious disease ward admission positively influences P. jiroveci pneumonia (PjP) outcome: A retrospective analysis of 116 HIV-positive and HIV-negative immunocompromised patients.

PLoS One 2017 15;12(5):e0176881. Epub 2017 May 15.

Infectious Diseases, Tor Vergata University, Rome, Italy.

P. jiroveci (Pj) causes a potentially fatal pneumonia in immunocompromised patients and the factors associated with a bad outcome are poorly understood. A retrospective analysis on Pj pneumonia (PjP) cases occurring in Tor Vergata University Hospital, Italy, during the period 2011-2015. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0176881PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5432209PMC
September 2017
42 Reads

Efficacy and Safety of Dapsone Versus Trimethoprim/Sulfamethoxazol for Pneumocystis Jiroveci Prophylaxis in Children With Acute Lymphoblastic Leukemia With a Background of Ethnic Neutropenia.

J Pediatr Hematol Oncol 2017 04;39(3):203-208

*Child Health Department ‡Pharmacy Department, Sultan Qaboos University Hospital, Muscat, Oman †Department of Pediatrics, Faculty of Medicine, University of Alexandria, Alexandria, Egypt.

Study Objective: To study dapsone in comparison with trimethoprim/sulfamethoxazole (TMP/SMX) for Pneumocystis jiroveci (PJP) prophylaxis in children with acute lymphoblastic leukemia (ALL).

Design: A retrospective study with a prospective follow-up.

Patients: Pediatric ALL patients diagnosed between May 2009 and May 2014, who are still receiving or have completed their maintenance chemotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MPH.0000000000000804DOI Listing
April 2017
11 Reads

Early use of corticosteroids in infants with a clinical diagnosis of Pneumocystis jiroveci pneumonia in Malawi: a double-blind, randomised clinical trial.

Paediatr Int Child Health 2017 May 1;37(2):121-128. Epub 2017 Feb 1.

a College of Medicine, University of Malawi , Blantyre , Malawi.

Background: Pneumocystis jiroveci pneumonia (PJP) is the most common opportunistic infection in infants with vertically acquired HIV infection and the most common cause of death in HIV-infected infants.

Objectives: To determine whether early administration of adjuvant corticosteroids in addition to standard treatment reduces mortality in infants with vertically acquired HIV and clinically diagnosed PJP when co-infection with cytomegalovirus and other pathogens cannot be excluded.

Methods: A double-blind placebo-controlled trial of adjuvant prednisolone treatment in HIV-exposed infants aged 2-6 months admitted to Queen Elizabeth Central Hospital, Blantyre who were diagnosed clinically with PJP was performed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/20469047.2016.1260891DOI Listing
May 2017
13 Reads

Pneumocystis jiroveci pneumonia in rheumatic disease: a 20-year single-centre experience.

Clin Exp Rheumatol 2017 Jul-Aug;35(4):671-673. Epub 2017 Jan 27.

Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, USA.

Objectives: Pneumocystis jiroveci pneumonia (PJP) is an opportunistic infection with high mortality among patients with underlying rheumatologic conditions. Given the paucity of prospective data to guide treatment, clinical guidelines to initiate PJP prophylaxis are based on expert opinion and identify patients on ≥20 mg daily prednisone for ≥4 weeks duration for treatment. Herein we describe the PJP experience in rheumatic disease over a 20-year period at a single academic medical centre to investigate this 20 mg threshold and risk associated with lymphocyte counts, co-existing lung disease and immunosuppressive medications. Read More

View Article

Download full-text PDF

Source
August 2017
5 Reads

Pneumocystis jiroveci pneumonia and GATA2 deficiency: Expanding the spectrum of the disease.

J Infect 2017 04 23;74(4):425-427. Epub 2017 Jan 23.

Department of Infectious Diseases, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Vasco de Quiroga 15, Col. Belisario Domínguez Sección XVI, Tlalpan, Mexico City, 14080, Mexico. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jinf.2017.01.005DOI Listing
April 2017
5 Reads

[Intrauterine Pneumocystis infection].

Ter Arkh 2016;88(11):99-102

N.F Gamaleya Federal Research Center for Epidemiology and Microbiology, Ministry of Health of Russia, Moscow, Russia.

Pneumocystosis is well known as an opportunistic infection that is presently most frequently registered in patients with HIV infection and in those with other immunodeficiency states. Earlier, after the Second World War, Pneumocystis pneumonia was most commonly detected in debilitated and premature children; nosocomial outbreaks of pneumocystosis were studied in detail in the 1960s and 1970s. The pathogen is transmitted through the air, but a number of references indicate that it can be transmitted through the placenta. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.17116/terarkh2016881199-102DOI Listing
August 2018
10 Reads

Dissemination of Trimethoprim-Sulfamethoxazole Drug Resistance Genes Associated with Class 1 and Class 2 Integrons Among Gram-Negative Bacteria from HIV Patients in South India.

Microb Drug Resist 2017 Jul 17;23(5):602-608. Epub 2016 Nov 17.

3 YRG Centre for AIDS Research and Education (YRG CARE), Voluntary Health Services Hospital Campus , Chennai, India .

The antibiotic, trimethoprim-sulfamethoxazole (TMP-SMX), is generally used for prophylaxis in HIV individuals to protect them from Pneumocystis jiroveci infection. Long-term use of TMP-SMX develops drug resistance among bacteria in HIV patients. The study was aimed to detect the TMP-SMX resistance genes among gram-negative bacteria from HIV patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/mdr.2016.0034DOI Listing
July 2017
9 Reads

Balancing the risks and benefits of prophylaxis: a reply to "Pneumocystis jiroveci pneumonia in patients treated with systemic immunosuppressive agents for dermatologic conditions".

Authors:
Kyle T Amber

Int J Dermatol 2017 01 22;56(1):e4-e5. Epub 2016 Sep 22.

Department of Dermatology, University of California Irvine, Irvine, CA, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ijd.13395
Publisher Site
http://dx.doi.org/10.1111/ijd.13395DOI Listing
January 2017
2 Reads

Prophylactic Trimethoprim-Sulfamethoxazole Does Not Affect Pharmacokinetics or Pharmacodynamics of Methotrexate.

J Pediatr Hematol Oncol 2016 08;38(6):449-52

Departments of *Pharmaceutical Sciences §Oncology †Biostatistics, St Jude Children's Research Hospital, Memphis, TN ‡Department of Pediatric Oncology, Skejby Hospital, Aarhus University, Aarhus, Denmark.

Trimethoprim-sulfamethoxazole (TMP/SMX) is used as prophylaxis against Pneumocystis jiroveci during chemotherapy. Many groups recommend withholding TMP/SMX during high-dose methotrexate (HDMTX) for concerns that it will delay methotrexate clearance. We compared methotrexate exposure following HDMTX (NCT00549848) in 424 patients including 783 courses that were given concurrently and 602 courses that were not given concurrently with TMP/SMX. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MPH.0000000000000606DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4955728PMC
August 2016
50 Reads

Radiological presentation of Pneumocystis jiroveci pneumonia mimicking bacterial pneumonia.

BMJ Case Rep 2016 Jun 3;2016. Epub 2016 Jun 3.

Intensive Care Unit, Alès General Hospital, Alès, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2016-215207DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4904393PMC
June 2016
4 Reads

The impact of trimethoprim-sulfamethoxazole as Pneumocystis jiroveci pneumonia prophylaxis on the occurrence of asymptomatic bacteriuria and urinary tract infections among renal allograft recipients: a retrospective before-after study.

BMC Infect Dis 2016 Feb 25;16:90. Epub 2016 Feb 25.

Department of Internal Medicine, Division of Infectious Diseases, Academic Medical Center-University of Amsterdam, PO box 22660, 1100 DD, Amsterdam, The Netherlands.

Background: The international guidelines recommend the administration of trimethoprim-sulfamethoxazole (TMP-SMX) as Pneumocystis jiroveci pneumonia (PJP) prophylaxis for six months after transplantation. The aim of this study is to evaluate the influence of TMP-SMX prophylaxis on the occurrence of asymptomatic bacteriuria (ASB) and urinary tract infections (UTIs) as cystitis and allograft pyelonephritis (AGPN) and its impact on the antimicrobial resistance pattern of causative microorganisms.

Methods: We have conducted a retrospective before-after study in adult renal allograft recipients with one year follow-up after transplantation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12879-016-1432-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4766656PMC
February 2016
34 Reads

The incidence, mortality and timing of Pneumocystis jiroveci pneumonia after hematopoietic cell transplantation: a CIBMTR analysis.

Bone Marrow Transplant 2016 Apr 4;51(4):573-80. Epub 2016 Jan 4.

Division of Hematology and Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC, USA.

Pneumocystis jiroveci pneumonia (PJP) is associated with high morbidity and mortality after hematopoietic stem cell transplantation (HSCT). Little is known about PJP infections after HSCT because of the rarity of disease given routine prophylaxis. We report the results of a Center for International Blood and Marrow Transplant Research study evaluating the incidence, timing, prophylaxis agents, risk factors and mortality of PJP after autologous (auto) and allogeneic (allo) HSCT. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/bmt2015316
Publisher Site
http://dx.doi.org/10.1038/bmt.2015.316DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823157PMC
April 2016
6 Reads

[Pneumocystosis in non-HIV-infected immunocompromised patients].

Rev Med Interne 2016 May 28;37(5):327-36. Epub 2015 Nov 28.

Maladies infectieuses et réanimation médicale, hôpital Pontchaillou, CHU de Rennes, 35033 Rennes, France. Electronic address:

Pneumocystis jiroveci (formerly P. carinii) is an opportunistic fungus responsible for pneumonia in immunocompromised patients. Pneumocystosis in non-HIV-infected patients differs from AIDS-associated pneumocystosis in mostly two aspects: diagnosis is more difficult, and prognosis is worse. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.revmed.2015.10.002DOI Listing
May 2016
1 Read

HIV-Related Opportunistic Infections Are Still Relevant in 2015.

Authors:
Henry Masur

Top Antivir Med 2015 Aug-Sep;23(3):116-9

George Washington University School of Medicine, Washington, DC, USA.

The incidence of HIV-related opportunistic infections (OIs) has declined in the United States with the increasing use of effective antiretroviral therapy for the treatment of HIV infection. However, the absolute number of patients with OIs remains high and there continues to be considerable associated mortality. OI guidelines from the National Institutes of Health, Centers for Disease Control and Prevention, and Infectious Diseases Society of America continue to be updated on a regular basis, several times per year, as optimal strategies for prevention and therapy evolve. Read More

View Article

Download full-text PDF

Source
https://www.iasusa.org/sites/default/files/tam/23-3-116.pdf
Web Search
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6148932PMC
May 2016
7 Reads

Pneumocystis jiroveci pneumonia (PCP) in patients receiving neoadjuvant and adjuvant anthracycline-based chemotherapy for breast cancer: incidence and risk factors.

Breast Cancer Res Treat 2015 Nov 29;154(2):359-67. Epub 2015 Sep 29.

Dana-Farber Cancer Institute, Boston, MA, USA.

Opportunistic infection with Pneumocystis jiroveci pneumonia (PCP) has not been recognized as a significant complication of early-stage breast cancer treatment. However, we have observed an increase in PCP incidence among patients receiving chemotherapy for early-stage breast cancer. Herein we identify risk factors for and calculate incidence of PCP in this population. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-015-3573-2DOI Listing
November 2015
15 Reads

Outcomes of Patients with Respiratory Distress Treated with Bubble CPAP on a Pediatric Ward in Malawi.

J Trop Pediatr 2015 Dec 11;61(6):421-7. Epub 2015 Sep 11.

Paediatric Department, College of Medicine, Blantyre 3, Malawi.

Objective: To describe the outcomes of infants and young children with respiratory distress when treated with a novel, low-cost, stand-alone bubble Continuous Positive Airway Pressure (bCPAP) system in a resource-limited setting.

Methods: A non-randomized, convenience sample study in a pediatric unit in Blantyre, Malawi, 2013. Patients weighing ≤10 kg with respiratory distress were eligible. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/tropej/fmv052DOI Listing
December 2015
30 Reads
1 Citation
0.860 Impact Factor

[Extrapulmonary pneumocystosis: a case report].

Rev Chilena Infectol 2015 Jun;32(3):344-9

We report a case of a middle-age male patient, with newly HIV infection in AIDS stage diagnosis, no comorbitidies, who was hospitalized for subacute malaise, fever, self-limited unproductive cough and no bloody chronic diarrea. The diagnosis of Pneumocystis jiroveci pneumonia was performed by imagenological suspicion and stains of cysts of this pathogen with bronchoalveolar lavage samples. Treatment was initiated with oral cotrimoxazole and starting HAART with good clinical outcome. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4067/S0716-10182015000400015DOI Listing
June 2015
3 Reads

Cost-effectiveness of Prophylaxis Against Pneumocystis jiroveci Pneumonia in Patients with Crohn's Disease.

Dig Dis Sci 2015 Dec 16;60(12):3743-55. Epub 2015 Jul 16.

Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, 27599, USA.

Background: Emerging evidence suggests that Pneumocystis jiroveci pneumonia is occurring more frequently in Crohn's disease patients on immunosuppressive medications, especially corticosteroids. Considering its excess mortality and the efficacy of chemoprophylaxis in reducing P. jiroveci pneumonia in acquired immunodeficiency syndrome, there is debate without consensus on the need for chemoprophylaxis in Crohn's disease patients on corticosteroids. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10620-015-3796-4DOI Listing
December 2015
7 Reads

[Pneumocystis jiroveci infection in patients with and without HIV: A comparison].

Rev Chilena Infectol 2015 Apr;32(2):175-80

Background: Respiratory infection caused by Pneumocystis jiroveci is a common opportunistic infection in patients with human immunodeficiency virus (HIV) with CD4 counts < 200 cells/mm(3). However, it has also been reported in patients with other causes of immunosuppression.

Objectives: To compare the characteristics, severity and mortality of respiratory infection by P. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4067/S0716-10182015000300006DOI Listing
April 2015
3 Reads

Pneumocystis jiroveci pneumonia with recurrent pneumothorax requiring pleurodesis in inflammatory bowel disease.

J Dig Dis 2015 Jul;16(7):416-9

Department of Medicine, Weill Cornell Medical Center, New York Presbyterian Hospital, New York, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1751-2980.12257DOI Listing
July 2015
9 Reads

Apical Pneumocystis jiroveci as an AIDS defining illness: A case report illustrating a change in the paradigm.

J Radiol Case Rep 2014 Nov 30;8(11):15-24. Epub 2014 Nov 30.

Department of Radiology, Yale New Haven hospital, New Haven, CT, USA.

Pneumocystis jiroveci pneumonia is a common acquired immune deficiency syndrome defining illness. Pneumocystis jiroveci pneumonia is classically described as having symmetrical bilateral perihilar ground-glass opacities on chest radiographs. We present an "atypical" case of Pneumocystis jiroveci pneumonia presenting as symmetric biapical cystic spaces with relative sparing of the remainder of the lungs in a 22 year-old male, previously undiagnosed with acquired immune deficiency syndrome. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3941/jrcr.v8i11.1772DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4394979PMC
November 2014
10 Reads

Prophylaxis and Treatment of Pneumocystis jiroveci Pneumonia in Lymphoma Patients Subjected to Rituximab-Contained Therapy: A Systemic Review and Meta-Analysis.

PLoS One 2015 24;10(4):e0122171. Epub 2015 Apr 24.

Department of Respiratory Medicine, Anhui Provincial Hospital, Hefei, China.

Pneumocystis jiroveci pneumonia (PCP) is frequently reported in lymphoma patients treated with rituximab-contained regimens. There is a trend toward a difference in PCP risk between bi- and tri-weekly regimens. The aims of this systemic review and meta-analysis were to estimate the risk for PCP in these patients, compare the impact of different regimens on the risk, and evaluate the efficacy of prophylaxis. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0122171PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4409297PMC
January 2016
6 Reads

Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection.

Cochrane Database Syst Rev 2015 Apr 2(4):CD006150. Epub 2015 Apr 2.

Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel (USB), Hebelstrasse 10, Basel, Switzerland, 4031.

Background: Pneumocystis jiroveci pneumonia (PCP) remains the most common opportunistic infection in patients infected with the human immunodeficiency virus (HIV). Among patients with HIV infection and PCP the mortality rate is 10% to 20% during the initial infection and this increases substantially with the need for mechanical ventilation. It has been suggested that corticosteroids adjunctive to standard treatment for PCP could prevent the need for mechanical ventilation and decrease mortality in these patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/14651858.CD006150.pub2DOI Listing
April 2015
1 Read

Prophylaxis for Pneumocystis jiroveci pneumonia: is it a necessity in pulmonary patients on high-dose, chronic corticosteroid therapy without AIDS?

Expert Rev Respir Med 2015 Apr;9(2):171-81

Department of Pulmonary, Critical Care, and Sleep Medicine, Carilion Clinic, P.O. Box 13367, Roanoke, VA 24033, USA.

The benefit of prophylaxis for Pneumocystis jirovecii pneumonia (PJP) is well documented in immunocompromised patients, particularly those with HIV and/or AIDS; therefore, guidelines dictate this as standard of care. However, there is a paucity of literature regarding those without HIV and/or AIDS who are potentially predisposed to PJP, including patients with sarcoidosis, cryptogenic organizing pneumonia, interstitial lung disease, asthma and chronic obstructive pulmonary disease, who may require high dose of prolonged corticosteroids for disease maintenance or to prevent relapses. In this review, the authors examine the available literature regarding prophylaxis in these groups, elaborate on the pathogenesis of PJP, when to suspect PJP in these patients, as well as explore current recommendations that guide clinical practice regarding implementation of PJP prophylaxis, namely with trimethoprim/sulfamethoxazole being the preferred agent. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17476348.2015.1002471DOI Listing
April 2015
10 Reads

Intravenous pentamidine for Pneumocystis carinii/jiroveci pneumonia prophylaxis in pediatric transplant patients.

Pediatr Transplant 2015 May 25;19(3):326-31. Epub 2015 Feb 25.

Pharmacy Department, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.

SMX/TMP is the current gold standard for prophylaxis against PCP in immunocompromised pediatric patients. Currently, there are several second-line options for prophylaxis but many, including intravenous (IV) pentamidine, have not been reported to be as effective or as safe as SMX/TMP in the pediatric transplant population. This study is to determine the efficacy and safety of IV pentamidine in preventing PCP in pediatric transplant patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/petr.12441DOI Listing
May 2015
13 Reads

A novel intronic splice site deletion of the IL-2 receptor common gamma chain results in expression of a dysfunctional protein and T-cell-positive X-linked Severe combined immunodeficiency.

Int J Immunogenet 2015 Feb 28;42(1):11-4. Epub 2014 Nov 28.

Immunology and Infectious Diseases, Sydney Children's Hospital, Sydney, NSW, Australia; School of Women's and Children's Health, University of New South Wales, Sydney, NSW, Australia.

X-linked severe combined immunodeficiency is caused by mutations in the IL-2 receptor common gamma chain and classically presents in the first 6 months of life with predisposition to bacterial, viral and fungal infections. In most instances, affected individuals are lymphopenic with near complete absence of T cells and NK cells. We report a boy who presented at 12 months of age with Pneumocystis jiroveci pneumonia and a family history consistent with X-linked recessive inheritance. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/iji.12166DOI Listing
February 2015
5 Reads

[Pneumocystis jiroveci pneumonia: comparative study of cases in HIV-infected patients and immunocompromised non-HIV-infected patients].

Rev Chilena Infectol 2014 Aug;31(4):417-24

Background: Although P. jiroveci pneumonia affects immunocompromised (IC) patients of any etiology, clinical features and prognostic outcomes are different depending if they are patients with HIV infection or other causes of IC.

Objectives: To compare clinical and laboratory features as well as outcomes of P. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4067/S0716-10182014000400007DOI Listing
August 2014
4 Reads

Quantification of the effect of chemotherapy and steroids on risk of Pneumocystis jiroveci among hospitalized patients with adult T-cell leukaemia.

Br J Haematol 2015 Feb 30;168(4):501-6. Epub 2014 Sep 30.

Department of Healthcare Administration and Management, Graduate School of Healthcare Sciences, Kyushu University, Fukuoka, Japan.

This study aimed to quantify the risks of Pneumocystis pneumonia (PCP) among adult T-cell leukaemia (ATL) patients without prophylaxis. We used hospital administrative data collected nationwide in Japan over 4 years. The research design was a retrospective cohort study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.13154DOI Listing
February 2015
7 Reads

Coinfection of Pneumocystis jiroveci pneumonia and pulmonary tuberculosis in a non-HIV-infected patient.

J Microbiol Immunol Infect 2015 Dec 27;48(6):711-2. Epub 2014 Aug 27.

Division of Pulmonary Medicine, Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jmii.2014.07.001DOI Listing
December 2015
2 Reads

Clindamycin-primaquine for pneumocystis jiroveci pneumonia in renal transplant patients.

Infection 2014 Dec 29;42(6):981-9. Epub 2014 Aug 29.

Division of Nephrology and Intensive Care, Department of Internal Medicine, Campus Virchow-Klinikum, Charité-University Medicine Berlin, Berlin, Germany.

Background: Trimethoprim/sulfamethoxazole (TMP/SMX) is considered first-line therapy for pneumocystis jiroveci pneumonia (PCP) in renal transplant patients. Alternatives have not been formally studied. Clindamycin-primaquine (C-P) is effective in HIV-associated PCP, but data in renal transplant patients are lacking. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s15010-014-0660-yDOI Listing
December 2014

Molecular epidemiology of Pneumocystis jiroveci in human immunodeficiency virus-positive and -negative immunocompromised patients in The Netherlands.

J Med Microbiol 2014 Oct 24;63(Pt 10):1294-302. Epub 2014 Jul 24.

Department of Medical Microbiology, Maastricht University Medical Centre, Maastricht, The Netherlands Department of Medical Microbiology, Atrium Medical Centre, Heerlen, The Netherlands

Pneumocystis jiroveci infections can cause pneumocystis pneumonia (PCP) or lead to colonization without signs of PCP. Over the years, different genotypes of P. jiroveci have been discovered. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1099/jmm.0.076257-0DOI Listing
October 2014
5 Reads

Incidence of Pneumocystis jiroveci pneumonia among groups at risk in HIV-negative patients.

Am J Med 2014 Dec 21;127(12):1242.e11-7. Epub 2014 Jul 21.

Maladies Infectieuses et Réanimation Médicale, Hôpital Pontchaillou, Rennes, France; CIC-Inserm-0203, Faculté de Médecine, Université Rennes 1, Rennes, France; INSERM U835, Faculté de Médecine, Université Rennes 1, Rennes, France. Electronic address:

Background: Pneumocystis jiroveci pneumonia in human immunodeficiency virus (HIV)-negative immunocompromised patients is associated with high mortality rates. Although trimethoprim-sulfamethoxazole provides a very effective prophylaxis, pneumocystosis still occurs and may even be emerging due to suboptimal characterization of patients most at risk, hence precluding targeted prophylaxis.

Methods: We retrospectively analyzed all cases of documented pneumocystosis in HIV-negative patients admitted in our institution, a referral center in the area, from January 1990 to June 2010, and extracted data on their underlying condition(s). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.amjmed.2014.07.010DOI Listing
December 2014
10 Reads

Vancomycin resistant enterococcus bacteremia in a patient with Pneumocystis jiroveci pneumonia, granulocystic sarcoma and acute respiratory distress syndrome.

Pan Afr Med J 2014 23;17:49. Epub 2014 Jan 23.

Ege University School of Medicine, Department of Chest Diseases, Izmir, Turkey.

In this case report we aimed to present a patient with granulocytic sarcomaa, neutropenic fever, ARDS and Pneumocystis jirovecii pneumoniae that was hospitalized in our intensive care unit. The patient recovered and then developed vancomycin resistant enterococci (VRE) bacteremia due to port catheter during follow up. The patient had risk factors for VRE bacteremia and he was administered linezolide without removing the catheter. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.11604/pamj.2014.17.49.3246DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4085949PMC
April 2015
10 Reads

Pneumocystis jiroveci pneumonia in patients receiving dasatinib treatment.

Int J Infect Dis 2014 Aug 14;25:165-7. Epub 2014 Jun 14.

Division of Hematology-Oncology, Chang Gung Memorial Hospital, 5 Fu-Shing Street, Kweishan Township, Taoyuan 333, Taiwan.

Dasatinib may cause various adverse effects such as myelosuppression and pleural effusion. It is well known that dasatinib may affect cellular immunity, which leads to the subsequent risk of a myriad of infections and viral reactivations, especially cytomegalovirus. Pneumocystis jiroveci pneumonia (PJP) is an opportunistic infection that typically occurs in immunocompromised hosts. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijid.2014.04.030DOI Listing
August 2014
11 Reads

Pneumocystis jiroveci pneumonitis complicating ruxolitinib therapy.

BMJ Case Rep 2014 Jun 2;2014. Epub 2014 Jun 2.

Department of Infectious Diseases, The Wesley Hospital, Auchenflower, Queensland, Australia.

Ruxolitinib is a novel inhibitor of the Janus kinase (JAK) pathway that has become available for the treatment of myelofibrosis. There are increasing reports of opportunistic infections associated with ruxolitinib therapy. We present a case of Pneumocystis jiroveci pneumonitis complicating ruxolitinib therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2014-204950DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4054251PMC
June 2014
2 Reads

Usefulness of (1→3)β-D glucan in early diagnosing Pneumocystis jirovecii pneumonia: a case report.

Infez Med 2014 Mar;22(1):57-61

Department of Clinical Microbiology, Faculty of Medicine, Erciyes University, Kayseri, Turkey; Department of Hematology and Oncology, Faculty of Medicine, Erciyes University, Kayseri, Turkey; Department of Clinical Microbiology, Faculty of Medicine, Mustafa Kemal University, Hatay, Turkey.

Pneumocystis jirovecii pneumoniae (PJP) may be difficult to diagnose. Since pneumocystis cannot be cultured, the diagnosis of PJP requires microscopic examination to identify pneumocystis from induced sputum or bronchoalveolar lavage (BAL) fluid. In order to evaluate the usefulness of (1→3) beta-D-glucan (BDG) levels in the early diagnosis of PJP, we describe the case of PJP in a 25-year-old male with acute lymphoblastic leukaemia (ALL) admitted to hospital with progressive dyspnea and fever with chills. Read More

View Article

Download full-text PDF

Source
March 2014
5 Reads

Red fist and muscle weakness with a rare complication.

BMJ Case Rep 2014 Feb 20;2014. Epub 2014 Feb 20.

VUmc, Amsterdam, The Netherlands.

A 64-year-old man was referred to our hospital, for a second opinion, with fever, skin lesions and general muscle pain. He has been treated in another hospital with antibiotics on suspicion of erysipelas. A week later skin lesions developed on the metacarpophalangeal and proximal carpophalangeal joints of the hands and nose. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2013-202457DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3931948PMC
February 2014
3 Reads

[Comparison of Pneumocystis jiroveci pneumonia characteristics in patients with and without HIV infection].

Enferm Infecc Microbiol Clin 2014 Oct 16;32(8):545-7. Epub 2014 Feb 16.

Servei de Malalties Infeccioses, Hospital Universitari Vall d'Hebron, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eimc.2014.01.005DOI Listing
October 2014
8 Reads

[Pneumocystis jiroveci pneumonia: Clinical characteristics and mortality risk factors in an Intensive Care Unit].

Med Intensiva 2015 Jan-Feb;39(1):13-9. Epub 2014 Jan 31.

Servicio de Enfermedades Infecciosas, Hospital del Mar, Universidad Autónoma de Barcelona, Barcelona, España.

Objective: To describe the epidemiological characteristics of the population with Pneumocystis jiroveci (P. jiroveci) pneumonia, analyzing risk factors associated with the disease, predisposing factors for admission to an intensive care unit (ICU), and prognostic factors of mortality.

Design And Patients: A retrospective observational study was carried out, involving a cohort of patients consecutively admitted to a hospital in Spain from 1 January 2007 to 31 December 2011, with a final diagnosis of P. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.medin.2013.11.006DOI Listing
January 2017
7 Reads

A fatal case of acute interstitial pneumonia (AIP) in a woman affected by glioblastoma.

Curr Drug Saf 2014 Mar;9(1):73-6

Department of Pneumology and Internal Medicine, Istituto Figlie di S, Camillo, Cremona, Italy.

This report presents the case of a 67-year-old woman affected by glioblastoma. After a few days of adjuvant therapy with temozolomide and prophylaxis with trimetrophin-sulfamethoxazolo to prevent Pneumocystis Jiroveci, she had progressive and rapid worsening of symptoms with weakness, dyspnea and orthopnea. She had peripheral edema and proximal hyposthenia of the lower limbs. Read More

View Article

Download full-text PDF

Source
March 2014
43 Reads